The Thousand Oaks, Calif.-based biotech pharmaceutical company makes drugs that treat patients in 47 countries.
News about Amgen
Critics accused the Charging Bull's new Wall Street companion of being an advertisement in disguise.
But Dupixent's high cost could be a problem.
Hospitals win, health insurers not so much.
Why chemoprevention is so damn hard. (Part 1.)
They say a robust review process is needed to convince doctors and insurers new drugs have value.